Monash Bioethics Centre Officially Designated as World Health Organization Collaborating Centre for Bioethics

WHO Head-Quater in Geneva, Switzerland.  Copyright : WHO/Pierre Virot

On 21 July 2014, the Monash Bioethics Centre was officially designated as a World Health Organization (WHO) Collaborating Centre for Bioethics, with Michael Selgelid as Director.  This makes it one of 6 such centres worldwide—and part of a Global Network of such centres, with partners at University of Toronto, Columbia University, University of Miami, University of Zurich, and National University of Singapore.

Our work plan with WHO will primarily focus on:

  • Bioethics Education, Awareness-Rasing, and Capacity Building
  • Ethics and Infectious Disease Control
  • Research Ethics
  • Collaboration with the Global Network of Collaborating Centres for Bioethics

 

For more information about WHO Collaborating Centres, click here

 

For more information about  the Global Network of WHO Collaborating Centres for Bioethics, click here

 

For more details on the Monash-WHO collaborative work plan, click here

 

For story in Monash News, click here

 

For coverage in The Australian, click here

 

Summary of SBS, World News Radio, interview with Michael Selgelid  on 26 August 2014:

“Monash University Centre for Human Bioethics is set to play a key role in how the world responds to infectious diseases like the ebola outbreak in west Africa as it looks to support the World Health Organisation in awareness raising in ethics and health, and devising policies for infectious diseases. Professor Michael Selgelid, Director of the new centre says that he has been involved in meetings recently about the ebola public health emergency in west Africa and whether it is acceptable to use experimental, untested medications against ebola. He says that it was decided in this extreme scenario that it is ethically acceptable to attempt experimental medications providing they seemed promising and proper, informed consent was given. Selgelid explains the logic behind who is given treatment priority for infectious diseases.”